View Amendment Current Amendment: H-3793 -1.docx to Bill 3793     The Committee on Medical Affairs proposed the following amendment (H-3793 -1):
    Amend the bill, as and if amended, by striking all after the enacting words and inserting:

/             SECTION 1.     Section 44-53-160 of the 1976 Code, as last amended by Act 273 of 2010, is further amended to read:

    "Section 44-53-160.(A)(1)         Annually, within thirty days after the convening of each regular session of the General Assembly, the department shall recommend to the General Assembly any additions, deletions, or revisions in the schedules of controlled substances, enumerated in Sections 44-53-190, 44-53-210, 44-53-230, 44-53-250, and 44-53-270, which it the department deems necessary. The Except as otherwise provided in this section, the department shall not make any additions, deletions, or revisions in such the schedules until after notice and an opportunity for a hearing is afforded to all interested parties. In making a recommendation to the General Assembly regarding a substance, the department shall consider the following:
            (a)     The the actual or relative potential for abuse;
            (b)     The the scientific evidence of its the substance's pharmacological effect, if known;
            (c)     State the state of current scientific knowledge regarding the substance;
            (d)     The the history and current pattern of abuse;
            (e)     The the scope, duration, and significance of abuse;
            (f)     The the risk to the public health;
            (g)     The the potential of the substance to produce psychic or physiological dependence liability; and
            (h)     Whether whether the substance is an immediate precursor of a substance already controlled under this Division pursuant to this chapter; and
            (i)         whether the substance has an accepted or recognized medical use.
        (2)     After considering the above factors listed in subsection (A)(1), the department shall make a recommendation to the General Assembly, specifying to what schedule the substance should be added, deleted, or rescheduled, if it the department finds that the substance has a potential for abuse.
    (3)(B)     During Except as otherwise provided in this section, during the time the General Assembly is not in session, the department may by rule add, delete, or reschedule a substance as a controlled substance after providing for notice and a hearing to all interested parties. The addition, deletion, or rescheduling of a substance pursuant to this subsection has the full force of law unless overturned by the General Assembly. Upon the adoption of such rule addition, deletion, or rescheduling of a substance, the department shall forward copies of the change to the chairmen of the Medical Affairs Committee and the Judiciary Committee of the Senate, and the Military, Public and Municipal Affairs Committee, and the Judiciary Committee of the House of Representatives, and to the Clerks of the Senate and House and to the Chairman of the Joint Legislative Committee on Drugs and Narcotics, and shall post the schedules on the department's website indicating the change and specifying the effective date of the change.
    (4)(C)     If any a substance is added, deleted, or rescheduled as a controlled substance under pursuant to federal law or regulation, the department department shall by rule, at its the first regular or special meeting of the South Carolina Board of Health and Environmental Control within thirty days after publication in the federal register of the final order designating the substance as a controlled substance or rescheduling or deleting the substance, add, delete, or reschedule the substance into in the appropriate schedule, such rule having. The addition, deletion, or rescheduling of a substance by the department pursuant to this subsection has the full force of law unless overturned by the General Assembly. This rule issued The addition, deletion, or rescheduling of a substance by the department shall department pursuant to this subsection must be in substance identical with the order published in the federal register effecting the change in federal status of the substance. The department shall notify the General Assembly in writing of the change in federal law or regulation and of the corresponding change in South Carolina law Upon the addition, deletion, or rescheduling of a substance, the department shall forward copies of the change to the chairmen of the Medical Affairs Committee and the Judiciary Committee of the Senate, the Military, Public and Municipal Affairs Committee, and the Judiciary Committee of the House of Representatives, and to the Clerks of the Senate and House, and shall post the schedules on the department's website indicating the change and specifying the effective date of the change.
    (5)(D)     The department shall exclude any nonnarcotic substance from a schedule if the substance may, under the federal Food, Drug, and Cosmetic Act and the law laws of this State, be lawfully sold over the counter without a prescription.
    (E)     The department's addition, deletion, or rescheduling of a substance as a controlled substance is governed by this section and is not subject to the promulgation requirements of Title 1, Chapter 23."

SECTION     2.     Section 44-53-190 of the 1976 Code, as last amended by Act 267 of 2002, is further amended to read:

    "Section 44-53-190.     (aA)     The controlled substances listed in this section are included in Schedule I.
    (bB)     Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation:
        1.         Acetylmethadol
        2.         Allylprodine
        3.         Alphacetylmethadol
        4.         Alphameprodine
        5.         Alphamethadol
        6.         Benzethidine
        7.         Betacetylmethadol
        8.         Betameprodine
        9.         Betamethadol
        10.     Betaprodine
        11.     Clonitazene
        12.     Dextromoramide
        13.     [Deleted]
        14.     Diampromide
        15.     Diethylthiambutene
        16.     Dimenoxadol
        17.     Dimepheptanol
        18.     Dimethylthiambutene
        19.     Dioxaphetyl butyrate
        20.     Dipipanone
        21.     Ethylmethylthiambutene
        22.     Etonitazene
        23.     Etoxeridine
        24.     Furethidine
        25.     Hydroxypethidine
        26.     Ketobemidone
        27.     Levomoramide
        28.     Levophenacylmorphan
        29.     Morpheridine
        30.     Noracymethadol
        31.     Norlevorphanol
        32.     Normethadone
        33.     Norpipanone
        34.     Phenadoxone
        35.     Phenampromide
        36.     Phenomorphan
        37.     Phenoperidine
        38.     Piritramide
        39.     Proheptazine
        40.     Properidine
        41.     Racemoramide
        42.     Trimeperidine
        43.     Propiram
        44.     Difenoxin
        45.     Alfentanyl
        46.     Tilidine
        47.     Alphamethylfentanyl (N- [1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl-4-(N-propanilido) piperidine).
    (cC)     Any of the following opium derivatives, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
        1.         Acetorphine
        2.         Acetyldihydrocodeine
        3.         Benzylmorphine
        4.         Codeine methylbromide
        5.         Codeine-N-Oxide
        6.         Cyprenorphine
        7.         Desomorphine
        8.         Dihydromorphine
        9.         Etorphine
        10.     Heroin
        11.     Hydromorphinol
        12.     Methyldesorphine
        13.     Methylhydromorphine
        14.     Morphine methylbromide
        15.     Morphine methylsulfonate
        16.     Morphine-N-Oxide
        17.     Myrophine
        18.     Nicocodeine
        19.     Nicomorphine
        20.     Normorphine
        21.     Pholcodine
        22.     Thebacon
        23.     Drotebanol
    (dD)         Any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
        1.         3,4-methylenedioxy amphetamine
        2.         5-methoxy-3,4-methylenedioxy amphetamine
        3.         3,4-methylenedioxymethamphetamine (MDMA)
        4.         3,4,5-trimethoxy amphetamine
        5.         Bufotenine
        6.         Diethyltryptamine (DET)
        7.         Dimethyltryptamine (DMT)
        8.         4-methyl-2,5-dimethoxyamphetamine (STP)
        9.         Ibogaine
        10.     Lysergic acid diethylamide (LSD)
        11.     Marijuana
        12.     Mescaline
        13.     Peyote
        14.     N-ethyl-3-piperidyl benzilate
        15.     N-methyl-3-piperidyl benzilate
        16.     Psilocybin
        17.     Psilocyn
        18.     Tetrahydrocannabinol (THC)
        19.     2,5-dimethoxyamphetamine
        20.     4-bromo-2,5-dimethoxyamphetamine
        21.     4-Methoxyamphetamine
        22.     Thiophene analog of phencyclidine
        23.     Parahexyl
        24.     Synthetic cannabinoids. - Any material, compound, mixture, or preparation that is not listed as a controlled substance in Schedule I through V, is not an FDA-approved drug, and contains any quantity of the following substances, their salts, isomers (whether optical, positional, or geometric), homologues, and salts of isomers and homologues, unless specifically excepted, whenever the existence of these salts, isomers, homologues, and salts of isomers and homologues is possible within the specific chemical designation:
            a.     Naphthoylindoles. Any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Including, but not limited to, JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, JWH-398, AM-2201, WIN 55-212, AM-2201 (C1 analog), AM-1220.
            b.     Naphthylmethylindoles. Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
            c.     Naphthoylpyrroles. Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Including, but not limited to, JWH-307, JWH-370, JWH-176.
            d.     Naphthylmethylindenes. Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.
            e.     Phenylacetylindoles. Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Including, but not limited to, SR-18, RCS-8, JWH-203, JWH-250, JWH-251.
            f.     Cyclohexylphenols. Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent. Including, but not limited to, CP 47,497 (and homologues), cannabicyclohexanol, CP-55, 940.
            g.     Benzoylindoles. Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Including, but not limited to, AM-694, Pravadoline (WIN 48,098), RCS-4, AM-630, AM-1241, AM-2233.
            h.     2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-de]-1, 4-benzoxazin-6-yl]-1-napthalenylmethanone. (WIN 55,212-2).
            i.     9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) - 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol 7370. (HU-210, HU-211).
            j.     Adamantoylindoles. Any compound containing a 3-(1-adamantoyl)indole structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring system to any extent.
    (eE)     Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substance having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers if possible within the specific chemical designation:
        (1)     Mecloqualone;
        (2)     Methaqualone; or
        (3)     Gamma Hydroxybutyric Acid.
    (fF)     Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
        (1)     Fenethylline.;
        (2)     N-ethylamphetamine;
        (3)     Cathinone; or
        (4)     Substituted Cathinones.
Any compound (not being bupropion) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways:
            (a)     by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;
            (b)     by substitution at the 3-position with an alkyl substituent;
            (c)     by substitution at the nitrogen atom with alkyl or dialkyl groups, benzyl or methoxybenzyl groups; or
            (d)     by inclusion of the nitrogen atom in a cyclic structure.
Including, but not limited to: Methylone, Mephedrone, 3,4-Methylenedioxypyrovalerone (MDPV), Butylone, Methedrone, 4-Methylethcathinone, Flephedrone, Pentylone, Pentedrone, Buphedrone."

SECTION     3.     If any section, subsection, paragraph, subparagraph, sentence, clause, phrase, or word of this act is for any reason held to be unconstitutional or invalid, such holding shall not affect the constitutionality or validity of the remaining portions of this act, the General Assembly hereby declaring that it would have passed this act, and each and every section, subsection, paragraph, subparagraph, sentence, clause, phrase, and word thereof, irrespective of the fact that any one or more other sections, subsections, paragraphs, subparagraphs, sentences, clauses, phrases, or words hereof may be declared to be unconstitutional, invalid, or otherwise ineffective.

SECTION     4.     The repeal or amendment by this act of any law, whether temporary or permanent or civil or criminal, does not affect pending actions, rights, duties, or liabilities founded thereon, or alter, discharge, release or extinguish any penalty, forfeiture, or liability incurred under the repealed or amended law, unless the repealed or amended provision shall so expressly provide. After the effective date of this act, all laws repealed or amended by this act must be taken and treated as remaining in full force and effect for the purpose of sustaining any pending or vested right, civil action, special proceeding, criminal prosecution, or appeal existing as of the effective date of this act, and for the enforcement of rights, duties, penalties, forfeitures, and liabilities as they stood under the repealed or amended laws.

SECTION     5.     This act takes effect upon approval by the Governor.                     /

    Renumber sections to conform.
    Amend title to conform.